

Title (en)
CALCIUM RECEPTOR ACTIVE MOLECULES.

Title (de)
CALCIUMREZEPTOREN BEEINFLUSSENDE MOLEKÜLE.

Title (fr)
MOLECULES AGISSANT SUR LES RECEPTEURS DE CALCIUM.

Publication
EP 0657029 A4 19960207 (EN)

Application
EP 92919933 A 19920821

Priority
• US 74945191 A 19910823
• US 83404492 A 19920211
• US 9207175 W 19920821
• US 93416192 A 19920821

Abstract (en)
[origin: WO9304373A1] Method and composition useful for treating a patient having a disease characterized by an abnormal level of one or more components, the activity of which is regulated or affected by activity of one or more Ca²⁺ receptors. Novel compounds useful in these methods and compositions are also provided. The method includes administering to the patient a therapeutically effective amount of a molecule active at one or more Ca²⁺ receptors as an agonist or antagonist. Preferably, the molecule is able to act as either a selective agonist or antagonist at a Ca²⁺ receptor of one or more but not all cells chosen from the group consisting of parathyroid cells, bone osteoclasts, juxtaglomerular kidney cells, proximal tubule kidney cells, keratinocytes, parafollicular thyroid cells and placental trophoblasts and a pharmaceutically acceptable carrier.

IPC 1-7
G01N 33/566; G01N 33/567; C07C 211/02; C07C 211/16; C07C 211/27; C07H 21/00; C07K 5/00; C07K 7/00; C12N 15/12; A61K 38/00

IPC 8 full level
G01N 33/15 (2006.01); A61K 31/13 (2006.01); A61K 31/135 (2006.01); A61K 31/14 (2006.01); A61K 31/16 (2006.01); A61K 31/165 (2006.01); A61K 31/235 (2006.01); A61K 31/275 (2006.01); A61K 31/395 (2006.01); A61K 31/40 (2006.01); A61K 31/403 (2006.01); A61K 31/404 (2006.01); A61K 31/44 (2006.01); A61K 31/55 (2006.01); A61K 31/554 (2006.01); A61K 31/715 (2006.01); A61K 31/785 (2006.01); A61K 33/06 (2006.01); A61K 38/00 (2006.01); A61K 38/16 (2006.01); A61K 45/00 (2006.01); A61P 3/00 (2006.01); A61P 3/14 (2006.01); A61P 5/18 (2006.01); A61P 5/22 (2006.01); A61P 9/00 (2006.01); A61P 9/12 (2006.01); A61P 19/08 (2006.01); A61P 19/10 (2006.01); A61P 43/00 (2006.01); C07C 211/02 (2006.01); C07C 211/03 (2006.01); C07C 211/15 (2006.01); C07C 211/16 (2006.01); C07C 211/17 (2006.01); C07C 211/19 (2006.01); C07C 211/26 (2006.01); C07C 211/27 (2006.01); C07C 211/29 (2006.01); C07C 211/30 (2006.01); C07C 211/42 (2006.01); C07C 215/46 (2006.01); C07C 215/48 (2006.01); C07C 215/50 (2006.01); C07C 215/52 (2006.01); C07C 217/54 (2006.01); C07C 217/56 (2006.01); C07C 217/58 (2006.01); C07C 217/60 (2006.01); C07C 219/14 (2006.01); C07C 225/16 (2006.01); C07C 229/38 (2006.01); C07C 233/05 (2006.01); C07C 235/34 (2006.01); C07C 235/44 (2006.01); C07C 237/22 (2006.01); C07C 237/30 (2006.01); C07C 255/24 (2006.01); C07C 255/45 (2006.01); C07C 255/58 (2006.01); C07C 279/14 (2006.01); C07C 323/18 (2006.01); C07C 323/32 (2006.01); C07D 209/14 (2006.01); C07D 209/16 (2006.01); C07D 209/18 (2006.01); C07D 209/30 (2006.01); C07D 209/40 (2006.01); C07D 211/90 (2006.01); C07D 213/28 (2006.01); C07D 213/36 (2006.01); C07D 213/38 (2006.01); C07D 215/12 (2006.01); C07D 215/14 (2006.01); C07D 233/54 (2006.01); C07D 257/02 (2006.01); C07D 281/10 (2006.01); C07D 295/00 (2006.01); C07D 413/04 (2006.01); C07H 21/00 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 14/435 (2006.01); C07K 14/705 (2006.01); C08G 69/10 (2006.01); C12N 5/10 (2006.01); C12N 15/09 (2006.01); C12N 15/12 (2006.01); C12Q 1/02 (2006.01); G01N 33/50 (2006.01); G01N 33/566 (2006.01); G01N 33/567 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); G01N 33/84 (2006.01); C12R 1/91 (2006.01)

IPC 8 main group level
A61K (2006.01); G01N (2006.01)

CPC (source: EP US)
A61K 31/13 (2013.01 - EP); A61K 31/135 (2013.01 - EP); A61K 31/137 (2013.01 - EP); A61K 31/165 (2013.01 - EP); A61K 31/275 (2013.01 - EP); A61K 31/395 (2013.01 - EP US); A61K 31/40 (2013.01 - EP); A61K 31/44 (2013.01 - EP); A61K 31/55 (2013.01 - EP); A61K 31/70 (2013.01 - EP); A61K 31/715 (2013.01 - EP); A61K 38/16 (2013.01 - EP); A61P 3/00 (2017.12 - EP); A61P 3/14 (2017.12 - EP); A61P 5/18 (2017.12 - EP); A61P 5/22 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/12 (2017.12 - EP); A61P 19/08 (2017.12 - EP); A61P 19/10 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07C 211/27 (2013.01 - EP); C07C 211/29 (2013.01 - EP); C07C 211/30 (2013.01 - EP); C07C 211/42 (2013.01 - EP); C07C 215/52 (2013.01 - EP); C07C 217/58 (2013.01 - EP); C07C 217/60 (2013.01 - EP); C07C 225/16 (2013.01 - EP); C07C 229/38 (2013.01 - EP); C07C 233/05 (2013.01 - EP); C07C 255/58 (2013.01 - EP); C07D 209/14 (2013.01 - EP); C07D 209/16 (2013.01 - EP); C07D 209/18 (2013.01 - EP); C07D 213/38 (2013.01 - EP); C07D 233/64 (2013.01 - EP); C07K 14/705 (2013.01 - EP); G01N 33/5008 (2013.01 - EP); G01N 33/5011 (2013.01 - EP); G01N 33/502 (2013.01 - EP); G01N 33/5044 (2013.01 - EP); G01N 33/5091 (2013.01 - EP); G01N 33/566 (2013.01 - EP); G01N 33/567 (2013.01 - EP); G01N 33/6872 (2013.01 - EP); C07C 2601/14 (2017.04 - EP); C07C 2602/08 (2017.04 - EP); G01N 2500/10 (2013.01 - EP); G01N 2500/20 (2013.01 - EP); G01N 2800/04 (2013.01 - EP)

Citation (search report)
• [X] WO 8204052 A1 19821125 - CHINOIN GYOGYSZER ES VEGYESZET [HU], et al
• [X] EP 0009702 A1 19800416 - SCHERING CORP [US]
• [X] WO 9100853 A1 19910124 - UNIV NEW YORK [US]
• [X] EP 0395357 A2 19901031 - PFIZER [US], et al
• [X] EP 0015505 A1 19800917 - CIBA GEIGY AG [CH]
• [X] EP 0005848 A1 19791212 - CIBA GEIGY AG [CH]
• [X] EP 0007204 A1 19800123 - LILLY CO ELI [US]
• [X] EP 0101069 A1 19840222 - HOFFMANN LA ROCHE [CH]
• [A] US 4728660 A 19880301 - HAYNES DUNCAN H [US], et al
• [A] EP 0384740 A2 19900829 - DANA FARBER CANCER INST INC [US]
• [X] WO 8909834 A1 19891019 - SALK INST BIOTECH IND [US]
• [PX] WO 9113077 A1 19910905 - SALK INST BIOTECH IND [US], et al
• [DXA] CHEN, CHU J. ET AL: "THE DILTIAZEM ANALOG TA-3090 MIMICS THE ACTIONS OF HIGH EXTRACELLULAR CA²⁺ ON PARATHYROID FUNCTION IN DISPERSED BOVINE PARATHYROID CELLS", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 5, no. 6, pages 581 - 587

- [DXA] BROWN, E.M. ET AL: "NEOMYCIN MIMICS THE EFFECTS OF HIGH EXTRACELLULAR CALCIUM CONCENTRATIONS ON PARATHYROID FUNCTION IN DISPERSED BOVINE PARATHYROID CELLS", ENDOCRINOLOGY, vol. 128, no. 6, pages 3047 - 3054
- [DX] ZAIDI, M. ET AL: "INTRACELLULAR CALCIUM IN THE CONTROL OF OSTEOCLAST FUNCTION. II PARADOXICAL ELEVATION OF CYTOSOLIC FREE CALCIUM BY VERAPAMIL", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 167, no. 2, pages 807 - 812
- [X] MUFF, R. ET AL: "REGULATION OF HORMONE SECRETION AND CYTOSOLIC CA²⁺ IN PARATHYROID CELLS AND C-CELLS: ROLE OF VOLTAGE-SENSITIVE CA²⁺ CHANNELS", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 265, no. 1, 15 August 1988 (1988-08-15), pages 128 - 135
- [A] ZAIDI, M.: ""CALCIUM RECEPTORS" ON EUKARYOTIC CELLS WITH SPECIAL REFERENCE TO THE OSTEOCLAST", BIOSCIENCE REPORTS, vol. 10, no. 6, pages 493 - 507
- [DA] NEMETH, E.F. ET AL: "THE ROLE OF EXTRACELLULAR CALCIUM IN THE REGULATION OF INTRACELLULAR CALCIUM AND CELL FUNCTION", CELL CALCIUM, vol. 11, pages 319 - 321
- [DA] NEMETH, E.F. ET AL: "REGULATION OF CYTOSOLIC CALCIUM BY EXTRACELLULAR DIVALENT CATIONS IN C-CELLS AND PARATHYROID CELLS", CELL CALCIUM, vol. 11, pages 323 - 327
- [X] A. MIKAMI ET AL.: "Primary structure and functional expression of the cardiac dihydropyridine-sensitive calcium channel.", NATURE, vol. 340, 20 July 1989 (1989-07-20), LONDON GB, pages 230 - 233
- [X] H. KIM ET AL.: "Studies on the structural requirements for the activity of the skeletal muscle dihydropyridine receptor/slow Ca²⁺ channel", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 20, 15 July 1990 (1990-07-15), BALTIMORE, MD., USA, pages 11858 - 11863
- See references of WO 9304373A1

Cited by

WO2008121386A2; WO2010104882A1

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

DOCDB simple family (publication)

WO 9304373 A1 19930304; AT E312347 T1 20051215; AT E313321 T1 20060115; AU 2588992 A 19930316; AU 673500 B2 19961114; AU 711247 B2 19991007; AU 7197796 A 19970220; CA 2115828 A1 19930304; CA 2115828 C 20110920; CN 1067550 C 20010627; CN 1071333 A 19930428; DE 69233572 D1 20060112; DE 69233572 T2 20060831; DE 69233586 D1 20060126; DE 69233586 T2 20060928; DK 1281702 T3 20060418; EP 0657029 A1 19950614; EP 0657029 A4 19960207; EP 1281702 A2 20030205; EP 1281702 A3 20040107; EP 1281702 B1 20051221; EP 1296142 A2 20030326; EP 1296142 A3 20030502; EP 1296142 B1 20051207; EP 1632470 A2 20060308; EP 1632470 A3 20070718; ES 2256370 T3 20060716; HK 1053303 A1 20031017; IL 102917 A0 19930131; IL 102917 A 20001206; IL 122958 A0 19980816; IL 122958 A 20040725; JP 2001220356 A 20010814; JP 2728564 B2 19980318; JP 2860285 B2 19990224; JP 2887201 B2 19990426; JP 3256502 B2 20020212; JP H06510531 A 19941124; JP H09281109 A 19971031; JP H09328420 A 19971222; JP H11221095 A 19990817; KR 100251995 B1 20000601; MX 9204881 A 19930401; NO 940581 D0 19940221; NO 940581 L 19940425; RU 2147574 C1 20000420; RU 94020394 A 19970510; ZA 926360 B 19930330

DOCDB simple family (application)

US 9207175 W 19920821; AT 02016612 T 19920821; AT 02027563 T 19920821; AU 2588992 A 19920821; AU 7197796 A 19961125; CA 2115828 A 19920821; CN 92111580 A 19920822; DE 69233572 T 19920821; DE 69233586 T 19920821; DK 02016612 T 19920821; EP 02016612 A 19920821; EP 02027563 A 19920821; EP 05077693 A 19920821; EP 92919933 A 19920821; ES 02016612 T 19920821; HK 03105590 A 20030804; IL 10291792 A 19920823; IL 12295892 A 19920823; IL 12295898 A 19980116; JP 2000394979 A 20001226; JP 23213096 A 19960902; JP 23216596 A 19960902; JP 31363198 A 19981104; JP 50465092 A 19920821; KR 19940700536 A 19940222; MX 9204881 A 19920821; NO 940581 A 19940221; RU 94020394 A 19920821; ZA 926360 A 19920824